

# Bernd Schnabl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5402112/publications.pdf>

Version: 2024-02-01

140  
papers

14,362  
citations

29994

54  
h-index

21474

114  
g-index

145  
all docs

145  
docs citations

145  
times ranked

14863  
citing authors

#	ARTICLE	IF	CITATIONS
1	The gut-liver axis and the intersection with the microbiome. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 397-411.	8.2	905
2	Interactions Between the Intestinal Microbiome and Liver Diseases. <i>Gastroenterology</i> , 2014, 146, 1513-1524.	0.6	806
3	Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2017, 25, 1054-1062.e5.	7.2	748
4	New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. <i>Nature</i> , 2018, 560, 198-203.	13.7	722
5	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324.	1.8	685
6	Enteric dysbiosis associated with a mouse model of alcoholic liver disease. <i>Hepatology</i> , 2011, 53, 96-105.	3.6	636
7	Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. <i>Nature Medicine</i> , 2015, 21, 159-165.	15.2	562
8	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019, 575, 505-511.	13.7	493
9	Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. <i>Journal of Hepatology</i> , 2015, 63, 1272-1284.	1.8	463
10	Intestinal fungi contribute to development of alcoholic liver disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 2829-2841.	3.9	336
11	Acute-on-chronic liver failure in cirrhosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16041.	18.1	320
12	Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. <i>Journal of Hepatology</i> , 2012, 56, 1283-1292.	1.8	289
13	Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. <i>Cell Host and Microbe</i> , 2016, 19, 227-239.	5.1	284
14	Supplementation of Saturated Long-Chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-induced Liver Injury in Mice. <i>Gastroenterology</i> , 2015, 148, 203-214.e16.	0.6	266
15	Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 359-370.	6.1	236
16	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. <i>Gut</i> , 2019, 68, 1504-1515.	6.1	202
17	Methods to determine intestinal permeability and bacterial translocation during liver disease. <i>Journal of Immunological Methods</i> , 2015, 421, 44-53.	0.6	199
18	Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. <i>Hepatology</i> , 2018, 67, 2150-2166.	3.6	189

#	ARTICLE	IF	CITATIONS
19	Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. <i>Hepatology</i> , 2013, 58, 108-119.	3.6	187
20	Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 218-230.	2.4	187
21	Gut microbiome, liver immunology, and liver diseases. <i>Cellular and Molecular Immunology</i> , 2021, 18, 4-17.	4.8	182
22	Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. <i>Journal of Hepatology</i> , 2018, 69, 51-59.	1.8	178
23	Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal <i>Enterococcus</i> . <i>Nature Communications</i> , 2017, 8, 837.	5.8	174
24	Microbiome as a therapeutic target in alcohol-related liver disease. <i>Journal of Hepatology</i> , 2019, 70, 260-272.	1.8	170
25	The Gut Microbiota and Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 275-284.	2.3	166
26	Pyroptosis by caspase11/4&agravgasdermin&agrav pathway in alcoholic hepatitis in mice and patients. <i>Hepatology</i> , 2018, 67, 1737-1753.	3.6	165
27	Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. <i>FASEB Journal</i> , 2015, 29, 1043-1055.	0.2	156
28	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 71, 522-538.	3.6	151
29	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 396-405.	1.8	144
30	Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 561-568.e1.	2.4	128
31	The <i>Candida albicans</i> exotoxin candidalysin promotes alcohol-associated liver disease. <i>Journal of Hepatology</i> , 2020, 72, 391-400.	1.8	119
32	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021, 11, 1248-1267.	7.7	117
33	Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non&agravalcoholic fatty liver disease. <i>British Journal of Pharmacology</i> , 2018, 175, 469-484.	2.7	116
34	Microbiota and Fatty Liver Disease&agravthe Known, the Unknown, and the Future. <i>Cell Host and Microbe</i> , 2020, 28, 233-244.	5.1	115
35	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020, 69, 764-780.	6.1	112
36	Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. <i>Journal of Internal Medicine</i> , 2019, 286, 32-40.	2.7	111

#	ARTICLE	IF	CITATIONS
37	Toll-Like Receptor 2-Mediated Intestinal Injury and Enteric Tumor Necrosis Factor Receptor I Contribute to Liver Fibrosis in Mice. <i>Gastroenterology</i> , 2012, 143, 1330-1340.e1.	0.6	108
38	The microbiota in cirrhosis and its role in hepatic decompensation. <i>Journal of Hepatology</i> , 2021, 75, S67-S81.	1.8	107
39	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 159, 1839-1852.	0.6	103
40	Intestinal Microbiota Mediates the Susceptibility to Polymicrobial Sepsis-Induced Liver Injury by Granisetron Generation in Mice. <i>Hepatology</i> , 2019, 69, 1751-1767.	3.6	102
41	Origin of myofibroblasts in liver fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, S17.	3.4	99
42	Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2021, 33, 21-32.	7.2	98
43	Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 2313-2323.	1.4	92
44	Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. <i>Hepatology</i> , 2017, 65, 475-490.	3.6	91
45	Targeting the gut-liver-immune axis to treat cirrhosis. <i>Gut</i> , 2021, 70, 982-994.	6.1	88
46	Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease. <i>Seminars in Liver Disease</i> , 2016, 36, 331-339.	1.8	84
47	Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. <i>Gut Microbes</i> , 2020, 12, 1782157.	4.3	83
48	Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease. <i>Clinical Science</i> , 2018, 132, 199-212.	1.8	78
49	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 72, 2182-2196.	3.6	74
50	Host-Microbiome Interactions in Alcoholic Liver Disease. <i>Gut and Liver</i> , 2014, 8, 237-241.	1.4	73
51	Linking intestinal homeostasis and liver disease. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 264-270.	1.0	71
52	The fecal mycobiome in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 788-799.	1.8	66
53	Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G1018-G1036.	1.6	64
54	Gut microbiota, fatty liver disease, and hepatocellular carcinoma. <i>Liver Research</i> , 2018, 2, 43-51.	0.5	64

#	ARTICLE	IF	CITATIONS
55	Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1 $\alpha$ Transactivation in Steatohepatitis. <i>Cell Metabolism</i> , 2018, 27, 339-350.e3.	7.2	62
56	An Introduction to Next Generation Sequencing Bioinformatic Analysis in Gut Microbiome Studies. <i>Biomolecules</i> , 2021, 11, 530.	1.8	62
57	Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. <i>Gut Microbes</i> , 2020, 12, 1785251.	4.3	60
58	Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1069-1076.	1.4	55
59	Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G563-G573.	1.6	54
60	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. <i>Translational Research</i> , 2019, 209, 22-38.	2.2	51
61	$\beta$ -Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway. <i>Journal of Hepatology</i> , 2018, 69, 687-696.	1.8	48
62	Gut dysbiosis as a driver in alcohol-induced liver injury. <i>JHEP Reports</i> , 2021, 3, 100220.	2.6	46
63	Bacteriophages and their potential for treatment of gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 135-144.	8.2	46
64	Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. <i>Frontiers in Physiology</i> , 2021, 12, 699253.	1.3	45
65	Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-8.	0.7	42
66	Fast-Track Clearance of Bacteria from the Liver. <i>Cell Host and Microbe</i> , 2016, 20, 1-2.	5.1	39
67	Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G310-G322.	1.6	38
68	Immunoglobulin A and liver diseases. <i>Journal of Gastroenterology</i> , 2018, 53, 691-700.	2.3	38
69	A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 375, 210-214.	1.0	36
70	Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. <i>Frontiers in Immunology</i> , 2018, 9, 2082.	2.2	35
71	Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1878-1892.	1.1	35
72	Antimicrobial proteins: intestinal guards to protect against liver disease. <i>Journal of Gastroenterology</i> , 2019, 54, 209-217.	2.3	33

#	ARTICLE	IF	CITATIONS
73	Promises of microbiome-based therapies. <i>Journal of Hepatology</i> , 2022, 76, 1379-1391.	1.8	33
74	Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. <i>Gut Microbes</i> , 2020, 11, 265-275.	4.3	31
75	Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 463-464.	2.4	29
76	Cytolysin-positive <i>Enterococcus faecalis</i> is not increased in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2020, 40, 860-865.	1.9	29
77	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. <i>Journal of Hepatology</i> , 2014, 60, 1259-1267.	1.8	28
78	Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?. <i>Physiology</i> , 2020, 35, 261-274.	1.6	28
79	High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. <i>Hepatology Communications</i> , 2020, 4, 681-695.	2.0	28
80	Intestinal virome and therapeutic potential of bacteriophages in liver disease. <i>Journal of Hepatology</i> , 2021, 75, 1465-1475.	1.8	28
81	Aryl Hydrocarbon Receptor Deficiency in Intestinal Epithelial Cells Aggravates Alcohol-Related Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 233-256.	2.3	26
82	YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15184-15193.	3.3	24
83	From intestinal dysbiosis to alcohol-associated liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 595-605.	4.5	24
84	Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G585-G597.	1.6	23
85	Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co-metabolism in Patients With Alcoholic Hepatitis. <i>Hepatology Communications</i> , 2020, 4, 1168-1182.	2.0	22
86	Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 584342.	1.2	22
87	The gut mycobiome: a novel player in chronic liver diseases. <i>Journal of Gastroenterology</i> , 2021, 56, 1-11.	2.3	22
88	CR1g on liver macrophages clears pathobionts and protects against alcoholic liver disease. <i>Nature Communications</i> , 2021, 12, 7172.	5.8	22
89	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-ACH). <i>Liver International</i> , 2022, 42, 1109-1120.	1.9	20
90	Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 2604-2613.	1.4	19

#	ARTICLE	IF	CITATIONS
91	Risk factors for progression of and treatment options for NAFLD in children. <i>Clinical Liver Disease</i> , 2018, 11, 11-15.	1.0	19
92	Intestinal virome in patients with alcohol use disorder and after abstinence. <i>Hepatology Communications</i> , 2022, 6, 2058-2069.	2.0	18
93	Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 891-920.	2.3	17
94	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e289-e297.	2.4	17
95	Roles for the mycobiome in liver disease. <i>Liver International</i> , 2022, 42, 729-741.	1.9	16
96	Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research. <i>Biomedicines</i> , 2020, 8, 63.	1.4	15
97	Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. <i>Hepatology International</i> , 2022, 16, 359-370.	1.9	15
98	What is the potential role of antifibrotic agents for the treatment of liver disease?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2008, 5, 496-497.	1.7	14
99	Intestinal $\alpha$ 1-2-Fucosylation Contributes to Obesity and Steatohepatitis in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 293-320.	2.3	14
100	The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. <i>Translational Research</i> , 2021, 227, 1-14.	2.2	13
101	Microbial Products and Metabolites Contributing to Alcohol-Related Liver Disease. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000023.	1.5	13
102	Skin wound closure delay in metabolic syndrome correlates with SCF deficiency in keratinocytes. <i>Scientific Reports</i> , 2020, 10, 21732.	1.6	12
103	Differential Activation of Unconventional T Cells, Including iNKT Cells, in Alcohol-Related Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1061-1074.	1.4	12
104	Fungi-Bacteria Correlation in Alcoholic Hepatitis Patients. <i>Toxins</i> , 2021, 13, 143.	1.5	12
105	Gut Microbiome and Alcohol-associated Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1349-1359.	0.4	12
106	ROR $\gamma$ t phosphorylation protects against T $\alpha$ cell-mediated inflammation. <i>Cell Reports</i> , 2022, 38, 110520.	2.9	12
107	Liver cirrhosis and immune dysfunction. <i>International Immunology</i> , 2022, 34, 455-466.	1.8	12
108	Transcriptomic Profiling Identifies Novel Hepatic and Intestinal Genes Following Chronic Plus Binge Ethanol Feeding in Mice. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3592-3604.	1.1	11

#	ARTICLE	IF	CITATIONS
109	Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. <i>Frontiers in Physiology</i> , 2020, 11, 370.	1.3	11
110	Deficiency of Intestinal Î±1-2-Fucosylation Exacerbates Ethanol-Induced Liver Disease in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1842-1851.	1.4	11
111	Combined analysis of gut microbiota, diet and <i>PNPLA3</i> polymorphism in biopsy-proven non-alcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 1576-1591.	1.9	11
112	Microbiome of the Aerodigestive Tract in Health and Esophageal Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 12-18.	1.1	10
113	New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2021, 41, 087-102.	1.8	10
114	Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12687.	1.8	10
115	Liver capsule: Mechanisms of alcoholic hepatitis. <i>Hepatology</i> , 2016, 64, 276-276.	3.6	9
116	Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models. <i>Nuclear Medicine and Biology</i> , 2016, 43, 179-187.	0.3	9
117	Microbiota and Alcoholic Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1791-1792.	1.4	8
118	A Novel Mouse Model of Acute-to-Chronic Cholestatic Alcoholic Liver Disease: A Systems Biology Comparison With Human Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 87-101.	1.4	8
119	Persistent SARS-CoV-2 RNA Positive in Feces but Negative in Breastmilk: A Case Report of COVID-19 in a Breastfeeding Patient. <i>Frontiers in Medicine</i> , 2020, 7, 562700.	1.2	8
120	Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. <i>World Journal of Gastroenterology</i> , 2020, 26, 4933-4944.	1.4	8
121	Serum Acylcarnitines Associated with High Short-Term Mortality in Patients with Alcoholic Hepatitis. <i>Biomolecules</i> , 2021, 11, 281.	1.8	7
122	Role of the Gut Microbiota in Parenteral Nutrition-Associated Liver Disease: From Current Knowledge to Future Opportunities. <i>Journal of Nutrition</i> , 2022, 152, 377-385.	1.3	7
123	Editors' Introduction to the NAFLD and NASH Special Issue. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1211-1213.	1.1	6
124	Colesevelam Reduces Ethanol-Induced Liver Steatosis in Humanized Gnotobiotic Mice. <i>Cells</i> , 2021, 10, 1496.	1.8	6
125	Machine Learning Applied to Omics Datasets Predicts Mortality in Patients with Alcoholic Hepatitis. <i>Metabolites</i> , 2022, 12, 41.	1.3	6
126	Immune Response of an Oral Enterococcus faecalis Phage Cocktail in a Mouse Model of Ethanol-Induced Liver Disease. <i>Viruses</i> , 2022, 14, 490.	1.5	6



#	ARTICLE	IF	CITATIONS
127	Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder. <i>Metabolites</i> , 2022, 12, 433.	1.3	6
128	A semiparametric model for between-subject attributes: Applications to beta-diversity of microbiome data. <i>Biometrics</i> , 2022, 78, 950-962.	0.8	5
129	Development of a Robotic Shear Wave Elastography System for Noninvasive Staging of Liver Disease in Murine Models. <i>Hepatology Communications</i> , 2022, 6, 1827-1839.	2.0	5
130	Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West?. <i>Inflammatory Intestinal Diseases</i> , 2016, 1, 3-8.	0.8	4
131	Integrative Analysis of Metabolome and Microbiome in Patients with Progressive Alcohol-Associated Liver Disease. <i>Metabolites</i> , 2021, 11, 766.	1.3	3
132	Lamin Deficiency in the Liver Sets the Stage for Nonalcoholic Steatohepatitis Development in Males. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017, 4, 441-442.	2.3	2
133	Check your microbiota when taking the drug. <i>Hepatology</i> , 2018, 67, 18-20.	3.6	2
134	Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 36-44.	0.2	2
135	Transplanting a fibrogenic microbiota. <i>Hepatology</i> , 2014, 59, 1660-1661.	3.6	1
136	Targeting pathobionts for the treatment of alcohol-associated liver disease. <i>Liver International</i> , 2021, 41, 239-240.	1.9	1
137	Peroxisome proliferator-activated receptor- $\gamma$ as emerging target in liver disease. <i>Drug Development Research</i> , 2010, 71, 106-111.	1.4	0
138	Fibroblast growth factor inducible 14 as potential target in patients with alcoholic hepatitis. <i>Gut</i> , 2013, 62, 335-336.	6.1	0
139	Reply to: "Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?". <i>Journal of Hepatology</i> , 2018, 69, 1400-1401.	1.8	0
140	Update on the Role of the Gut Microbiota on Alcohol-Associated Liver Disease. <i>Gastroenterology and Hepatology</i> , 2021, 17, 381-383.	0.2	0